SCHEMBL5446366

SCHEMBL5446366

Cc1c(CC(=O)O)c2cc(O)c(F)cc2n1Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 13/20 0.61
PLA2G1B P04054 1/20 0.61
PTGDR2 Q9Y5Y4 3/20 0.57
LMNA P02545 2/20 0.55
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 2/20 0.55
CYP2C9 P11712 2/20 0.55
TSHR P16473 2/20 0.55
CYP2C19 P33261 2/20 0.55
PMP22 Q01453 2/20 0.55
KDM4E B2RXH2 1/20 0.55
BLM P54132 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
THRA P10827 1/20 0.54
THRB P10828 1/20 0.54
PTGES O14684 1/20 0.53
ALOX5 P09917 1/20 0.53
MEN1 O00255 1/20 0.51
RGS12 O14924 1/20 0.51
ALDH1A1 P00352 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5446135 0.92 LMNA (0.66) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5438283 0.92 LMNA (0.57) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5437543 0.92 LMNA (0.57) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5454133 0.91 LMNA (0.63) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5444234 0.90 PTGS2 (0.64) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5448597 0.88 LMNA (0.53) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5444370 0.88 LMNA (0.70) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5442571 0.88 PTGDR2 (0.58) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5436777 0.87 PTGDR2 (0.57) PLA2G2APLA2G1BPTGDR2LMNACYP1A2
SCHEMBL5435406 0.87 PLA2G2A (0.63) PLA2G2APLA2G1BPTGDR2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070161698-A1 Modulators of CRTH2 Activity MICROBIA, INC. 2007-07-12 US disclosed
US-20070161698-A1 Modulators of CRTH2 Activity MICROBIA, INC. 2007-07-12 US disclosed
US-7205329-B2 Modulators of CRTH2 activity MICROBIA, INC. (US) 2007-04-17 US disclosed
US-7205329-B2 Modulators of CRTH2 activity MICROBIA, INC. (US) 2007-04-17 US disclosed
US-20060135591-A1 Modulators of CRTH2 activity IRONWOOD PHARMACEUTICALS, INC. 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135591-A1 Modulators of CRTH2 activity HRH2, HRH1, MRGPRX2 PLA2G2A 431/4885PLA2G1B 543/4885PTGDR2 22/4885
US-20070161698-A1 Modulators of CRTH2 Activity HRH2, HRH1, MRGPRX2 PLA2G2A 431/4885PLA2G1B 543/4885PTGDR2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.